A Single Arm Phase II Study Assessing Efficacy of Stereotactic Radiosurgery (SRS) for Brain Metastasis (BM) From Small Cell Lung Cancer (SCLC)
Status: Recruiting
Location: See all (8) locations...
Intervention Type: Radiation, Procedure
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Histologic diagnosis of small cell lung cancer
• Radiographic diagnosis of up to 10 brain metastases on contrast-enhanced MRI
• Age 18 and above
• Performance status KPS 60-100/ECOG 0-2
• Female patients must be of non-reproductive potential or have a negative serum pregnancy test at the time of enrollment
• The patient or legally authorized representative is able to provide informed consent
Locations
United States
Connecticut
Hartford Healthcare (Data Collection Only)
RECRUITING
Hartford
New Jersey
Memorial Sloan Kettering at Basking Ridge
RECRUITING
Basking Ridge
Memorial Sloan Kettering Monmouth
RECRUITING
Middletown
Memorial Sloan Kettering Bergen
RECRUITING
Montvale
New York
Memorial Sloan Kettering Suffolk - Commack
RECRUITING
Commack
Memorial Sloan Kettering Westchester
RECRUITING
East White Plains
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITING
New York
Memorial Sloan Kettering Nassau
RECRUITING
Rockville Centre
Contact Information
Primary
Luke Pike, MD
PikeL@mskcc.org
201-775-7604
Backup
Brandon Imber, MD
imberb@mskcc.org
631-212-6346
Time Frame
Start Date: 2022-06-10
Estimated Completion Date: 2026-06-10
Participants
Target number of participants: 62
Treatments
Experimental: Participants with small cell lung cancer with brain metastases
Participants may be newly diagnosed small cell lung cancer with brain metastases at initial staging, or can alternatively be patients who develop brain metastases on therapy or during surveillance of systemic disease.
Related Therapeutic Areas
Sponsors
Leads: Memorial Sloan Kettering Cancer Center